Ascendis Pharma A (ASND) Cash from Operations (2014 - 2026)
Ascendis Pharma A (ASND) posted Cash from Operations of 9039327.16 for Q1 2026, up 92.69% sequentially from 123704068.35 in Q4 2025, and up 39.96% YoY from 6458486.62 in Q1 2025.
Ascendis Pharma A (ASND) Cash from Operations (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported Cash from Operations for 13 years, with the latest figure at 9039327.16 in Q1 2026.
- Quarterly Cash from Operations rose 39.96% year-over-year to 9039327.16 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 138536135.97 (up 41.27% YoY) and the FY2025 annual result came in at 146404080.93, up 55.26% from the prior year.
- Cash from Operations improved to 9039327.16 in Q1 2026 per ASND's latest filing, from 123704068.35 in the prior quarter.
- Over five years, Cash from Operations peaked at 2516975.61 in Q3 2025 and troughed at 166744814.28 in Q2 2023.
- A 5-year average of 89090117.61 and a median of 99650776.84 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations tumbled 103.86% in 2024, then soared 104.08% in 2025.
- Over 5 years, Cash from Operations stood at 144553747.95 in 2022, then soared by 68.39% to 45695167.93 in 2023, then sank by 103.86% to 93155872.6 in 2024, then sank by 32.79% to 123704068.35 in 2025, then jumped by 92.69% to 9039327.16 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 9039327.16, 123704068.35, and 2516975.61 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | -9.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.04 Mn |
| Mar 31, 2026 | -9.04 Mn |
| Dec 31, 2025 | -123.70 Mn |
| Dec 31, 2025 | -123.70 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Jun 30, 2025 | -8.31 Mn |
| Jun 30, 2025 | -8.31 Mn |
| Mar 31, 2025 | -15.06 Mn |
| Mar 31, 2025 | -15.06 Mn |
| Dec 31, 2024 | -93.16 Mn |
| Dec 31, 2024 | -93.16 Mn |
| Sep 30, 2024 | -61.64 Mn |
| Sep 30, 2024 | -61.64 Mn |
| Jun 30, 2024 | -66.02 Mn |
| Jun 30, 2024 | -66.02 Mn |
| Mar 31, 2024 | -110.35 Mn |
| Mar 31, 2024 | -110.35 Mn |
| Dec 31, 2023 | -45.70 Mn |
| Dec 31, 2023 | -45.70 Mn |